BOSTON– Sensible Biotechnologies has unveiled a powerful new approach to accelerating the design of cell-based mRNA therapeutics, cutting optimization time by more than 90% through the use of NVIDIA’s AI and accelerated computing technologies.
The Boston-based biotech firm is pioneering a cell-based platform for producing mRNA drugs, replacing traditional in vitro transcription methods with a system that manufactures therapeutic RNA inside living cells. This novel method results in highly pure, low-immunogenicity mRNA molecules—key for next-generation treatments targeting cancer, rare diseases, gene editing, and other complex conditions.
At the core of Sensible’s breakthrough is a proprietary, closed-loop AI platform that designs and optimizes mRNA sequences by modeling how RNA folds and stabilizes in biological environments. The company integrates cutting-edge NVIDIA technologies, including the NVIDIA BioNeMo framework, NIM microservices, and the DGX Cloud platform powered by NVIDIA Hopper GPUs.
The result is a dramatic boost in processing speed. Sensible now achieves over 11,000 simulation steps per second using DGX Cloud and NVIDIA H100 GPUs with 80 GB memory. This performance enables parallel screening of RNA sequences, reducing simulation runtimes from hours to under an hour per sequence. What previously took 15 days now takes just one.
“Producing therapeutic mRNA inside living cells requires solving intricate biological problems, from RNA folding to packaging,” said Krishna Motheramgari, PhD, Principal Computational Scientist at Sensible Biotechnologies. “With advanced NVIDIA AI, we can simulate these dynamics rapidly and accurately, accelerating our design cycle dramatically.”
By enabling rapid, precise, and scalable optimization, the partnership with NVIDIA has allowed Sensible to explore a wider range of mRNA designs and bring potential therapies to clinical readiness faster than ever before. CEO and co-founder Miroslav Gasparek said this capability is essential to realizing the company’s broader vision.
“By combining our cell-based platform with NVIDIA accelerated computing and AI, we’re laying the foundation for programmable, high-performance RNA medicines,” said Gasparek.
Sensible’s AI-driven platform offers not only increased speed but a new level of precision and adaptability for designing RNA therapeutics that meet the increasingly complex demands of modern medicine. The company sees its approach as critical to unlocking new possibilities for safe, effective, and scalable treatments in the fast-evolving field of mRNA-based therapies. (Source: IANS)
